新冠假病毒（SARS-CoV-2 Pseudotyped v

药诺基因--新冠SARS-CoV-2 (2019nCoV)假病毒一站式服务平台

新冠SARS-CoV-2假病毒及Spike蛋白突变株（D614G, S943P, V367F, G476S,
V483A, H49Y, Q239K, A831V, P1263L, D839Y/N/E: D839Y, D839N, D839E）

 

产品货号：GM-2019nCoV-PSV01~PSV13

报告基因：RFP和Firefly Luciferase
效应细胞：hACE2-HEK293T (Cat.GM-SC-293T-hACE201)
包  装：0.5mL/管

   产品介绍   
 

药诺基因提供的新冠SARS-CoV-2假病毒（GM-2019nCoV-PSV01~PSV13）是含有Spike蛋白的慢病毒颗粒，用于模拟SARS-CoV-2感染细胞和细胞侵入。

SARS-CoV-2假病毒颗粒基因组编码荧光素酶（Firefly Luciferase）和红色荧光蛋白（RFP）。在SARS-CoV-2假病毒进入表达ACE2的细胞后，Firefly Luciferase和RFP则会强表达。

人源 ACE2过表达的HEK293T稳转细胞系通常被用来作为效应细胞(GM-SC-293T-hACE2-01。

药诺基因提供的新冠SARS-CoV-2假病毒可用于SARS-CoV-2相关疫苗的疗效评估，中和抗体，多肽阻断剂竞争中和试验，还有组织特异性感染测定等。

    新冠SARS-CoV-2假病毒及Spike蛋白突变株产品列表    
 

Catalog No.	Pseudotyped virus of SARS-CoV-2 Spike Mutation Variants and Effector cells
GM-2019nCoV-PSV01-2	SARS-CoV-2 Pseudotyped virus packaging and production
GM-SC-293T‐hACE2-01	Human ACE2 overexpression stable HEK293T cell lines
GM-2019nCoV-PSV02	Spike D614G mutation SARS-CoV-2(2019nCoV) Pseudotyped virus
GM-2019nCoV-PSV03	Spike S943P mutation SARS-CoV-2(2019nCoV) Pseudotyped virus
GM-2019nCoV-PSV04	Spike V367F mutation SARS-CoV-2(2019nCoV) Pseudotyped virus
GM-2019nCoV-PSV05	Spike G476S mutation SARS-CoV-2(2019nCoV) Pseudotyped virus
GM-2019nCoV-PSV06	Spike V483A mutation SARS-CoV-2(2019nCoV) Pseudotyped virus
GM-2019nCoV-PSV07	Spike H49Y mutation SARS-CoV-2(2019nCoV) Pseudotyped virus
GM-2019nCoV-PSV08	Spike Q239K mutation SARS-CoV-2(2019nCoV) Pseudotyped virus
GM-2019nCoV-PSV09	Spike A831V mutation SARS-CoV-2(2019nCoV) Pseudotyped virus
GM-2019nCoV-PSV10	Spike P1263L mutation SARS-CoV-2(2019nCoV) Pseudotyped virus
GM-2019nCoV-PSV11	Spike D839Y/N/E-D839Y mutation SARS-CoV-2(2019nCoV) Pseudotyped virus
GM-2019nCoV-PSV12	Spike D839Y/N/E-D839N mutation SARS-CoV-2(2019nCoV) Pseudotyped virus
GM-2019nCoV-PSV13	Spike D839Y/N/E-D839E mutation SARS-CoV-2(2019nCoV) Pseudotyped virus
GM-2019nCoV-PSV14	P2-mutated Spike protein trimer variant (P2-mutant, S1/S2 cleavage site (furin cleavage sequence)-mutant, (trimerization modified) mutation SARS-CoV-2(2019nCoV) Pseudotyped virus
GM-2019nCoV-PSV15	Spike of SARS-COV-2 B.1.1.7 lineage mutation SARS-CoV-2(2019nCoV) Pseudotyped virus
GM-2019nCoV-PSV16	Spike(S1+S2) N501Y mutation SARS-CoV-2(2019nCoV) Pseudotyped virus
GM-2019nCoV-PSV17	Spike(S1+S2)-HV 69-70 Deletion mutation(ΔH69/ΔV70) SARS-CoV-2(2019nCoV) Pseudotyped virus
GM-2019nCoV-PSV18	Spike(S1+S2)-E484K mutation of SARS-CoV-2(2019nCoV) Pseudotyped virus (501Y.V2 lineage)
GM-2019nCoV-PSV19	Spike (S1+S2) RBD triple mutation(K417N, E484K and N501Y) of SARS-CoV-2(2019nCoV) Pseudotyped virus (501Y.V2 lineage)
GM-2019nCoV-PSV20	Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) 501Y.V2 lineage Pseudotyped virus
GM-2019nCoV-PSV21	Spike (S1+S2) RBD triple mutation(K417T, E484K and N501Y)+D614G of SARS-CoV-2(2019nCoV) Pseudotyped virus (Brazilian P.1 lineage)
GM-2019nCoV-PSV22	Spike whole mutant SARS-CoV-2(2019nCoV) Brazilian P.1 lineage Pseudotyped virus
GM-2019nCoV-PSV23	Spike(S1+S2) RBD-S477N mutation of SARS-CoV-2(2019nCoV) Pseudotyped virus (B.1.526 lineage; 20A.EU2 lineage) and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV24	Spike (S1+S2) RBD mutation (S477N)+ D253G of SARS-CoV-2(2019nCoV) Pseudotyped virus (B.1.526 lineage) production and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV25	Spike (S1+S2) RBD mutation (E484K)+ D253G of SARS-CoV-2(2019nCoV) Pseudotyped virus (B.1.526 lineage) production and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV26	Spike whole mutant SARS-CoV-2(2019nCoV) B.1.526 lineage Pseudotyped virus production and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV27	Spike(S1+S2) RBD-E484Q mutation of SARS-CoV-2(2019nCoV) Pseudotyped virus (double mutant variant EPI_ISL_1360318, S:E484Q+L452R (India)) and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV28	Spike (S1+S2) RBD mutation L452R of SARS-CoV-2(2019nCoV) Pseudotyped virus (double mutant variant EPI_ISL_1360318, S:E484Q+L452R (India)) production and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV29	Spike (S1+S2) RBD mutation (E484Q+L452R) of SARS-CoV-2(2019nCoV) Pseudotyped virus (double mutant variant EPI_ISL_1360318, S:E484Q+L452R (India)) production and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV30	Spike whole mutant SARS-CoV-2(2019nCoV) double mutant variant EPI_ISL_1360318, S:E484Q+L452R (India) Pseudotyped virus production and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV31	Spike(S1+S2) RBD-S477G mutation of SARS-CoV-2(2019nCoV) Pseudotyped virus (B.1.526 lineage) and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV32	Spike(S1+S2) RBD-T478K mutation of SARS-CoV-2(2019nCoV) Pseudotyped virus (delta variant B.1.617.2 lineage) and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV33	Spike (S1+S2) RBD mutation (L452R+T478K) of SARS-CoV-2(2019nCoV) Pseudotyped virus (delta variant B.1.617.2 lineage) production and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV34	Spike whole mutant SARS-CoV-2(2019nCoV) delta variant B.1.617.2 lineage Pseudotyped virus production and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV35	Spike (S1+S2) RBD mutation L452Q of SARS-CoV-2(2019nCoV) Pseudotyped virus (lambda variant C.37 lineage) production and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV36	Spike(S1+S2) RBD mutation F490S of SARS-CoV-2(2019nCoV) Pseudotyped virus (lambda variant C.37 lineage) and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV37	Spike (S1+S2) RBD mutation (L452Q+F490S) of SARS-CoV-2(2019nCoV) Pseudotyped virus (lambda variant C.37 lineage) production and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV38	Spike whole mutant SARS-CoV-2(2019nCoV) lambda variant C.37 lineage Pseudotyped virus production and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV39	Spike RBD mutation of SARS-CoV-2(2019nCoV) Pseudotyped virus (Omicron variant aka B.1.1.529) production and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV40	Spike whole mutant SARS-CoV-2(2019nCoV)Omicron variant aka B.1.1.529 Pseudotyped virus production and Pseudovirus Based Neutralization Assay

     新的突变系SARS-COV-2 (2019nCOV) -Omicron variant aka B.1.1.529 lineage    
目前，COVID-19疫情在全世界各地爆发，严重影响了人类的生活和生命健康。最近出现一种新的突变系称为“Omicron variant aka B.1.1.529 lineage”，最早在2021年11月9号收集的样本中出现。Omicron variant aka B.1.1.529 lineage具有大量突变，很多突变位点值得关注。下图和表是Omicron variant aka B.1.1.529 lineage spike区域的突变点:


Figure. Amino acid changes in the spike region of the Omicron variant aka B.1.1.529 lineage genomes1. Note: In our product, N211I→Δ211.

 

Spike Mutation in SARS-COV-2 (2019nCOV)  Omicron variant aka B.1.1.529 lineage	Spike-S1 Subunit N Terminal	A67V
		Δ69-70
		T95I
		G142D
		Δ143-145
		Δ211-212
		ins214EPE
	Spike-RBD	G339D	Important residues mutation Important residues mutation
		S371L
		S373P
		S375F
		K417N
		N440K
		G446S
		S477N
		T478K
		E484A
		Q493R
		G496S
		Q498R
		N501Y
		Y505H
	Spike-S1 Subunit	T547K
		D614G	A popular mutation in different new SARS-CoV-2 lineage
		H655Y
		N679K
		P681H
	Spike-S2 Subunit	N764K
		D796Y
		N856K
		Q954H
		N969K
		L981F

Table. Amino acid changes in the spike region of the Omicron variant aka B.1.1.529 lineage genomes.

GeneMedi为中和抗体开发提供SARS-COV-2 (2019nCOV) Omicron variant aka B.1.1.529 lineage假病毒（pseudotype virus）

Cat No.	Pseudotyped virus of SARS-CoV-2 Spike Mutation Variants
GM-2019nCoV-PSV39	Spike RBD mutation of SARS-CoV-2(2019nCoV) Pseudotyped virus (Omicron variant aka B.1.1.529) production and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV40	Spike whole mutant SARS-CoV-2(2019nCoV)Omicron variant aka B.1.1.529 Pseudotyped virus production and Pseudovirus Based Neutralization Assay

GeneMedi为开发和评价抗病毒化合物提供SARS-COV-2 (2019nCOV) Coronavirus Mpro (Coronavirus 3CLpro, 3C-Like protein)蛋白

Cat No.	Antigen Name of 2019-nCoV(SARS-CoV-2)	Source (Expression Host)
GMP-V-2019nCoV-Mpro001	Recombinant 2019nCoV antigen-coronavirus Main Proteinase (Mpro, 3CLpro, His Tag)	E.coli

GeneMedi提供SARS-COV-2 (2019nCOV) Omicron variant aka B.1.1.529 lineage中和抗体

Cat No.	Neutralizing antibody Name	Source (Expression Host)
GMP-V-2019nCoV-SnAb006	Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)	Mammalian (human cell)
GMP-V-2019nCoV-SnAb007	Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)	Mammalian (human cell)
GMP-V-2019nCoV-SnAb008	Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)	Mammalian (human cell)

GeneMedi提供SARS-COV-2 (2019nCOV) -Omicron variant aka B.1.1.529 lineage of Spike蛋白， Spike S-trimer蛋白及ACE2蛋白

Cat No.	Antigen Name of 2019-nCoV(SARS-CoV-2)	Source (Expression Host)
GMP-V-2019nCoV-Smu-027	Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein RBD mutant (Omicron variant aka B.1.1.529)	Mammalian (human cell)
GMP-V-2019nCoV-S-trimer-004	Recombinant 2019-nCoV(SARS-CoV-2) Spike S-trimer Protein (Omicron variant aka B.1.1.529  lineage) with furin cleavage site mutation & T4 fibritin trimerization motif	Mammalian (human cell)
GMP-H-ACE2001	Recombinant human solubale ACE2 protein (soluble hACE2,extracellular hACE2,C-His)	Mammalian (human cell)
GMP-H-ACE2002	Recombinant human solubale ACE2 protein (soluble hACE2,extracellular hACE2,C-FC)	Mammalian (human cell)

GeneMedi提供密码子优化的SARS-COV-2 (2019nCOV) -Omicron variant aka B.1.1.529 lineage Spike及Spike RBD的pcDNA3.1(+)、腺病毒、慢病毒载体.

Cat No.	Gene &Vector description of 2019 nCoV	Vector	Tag	Coden Optimized
GMV-V-2019nCoV-192	pGM-Spike RBD mutation of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529	pcDNA3.1(+)	No tag	coden optimized for mamamlian
GMV-V-2019nCoV-193	Ad-Spike RBD mutation of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529	Pre-made adenovirus	C-3FLAG	coden optimized for mamamlian
GMV-V-2019nCoV-194	pGMLV-Spike RBD mutation of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529	Lentiviral vector	C-3FLAG	coden optimized for mamamlian
GMV-V-2019nCoV-195	pGM-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529	pcDNA3.1(+)	No tag	coden optimized for mamamlian
GMV-V-2019nCoV-196	Ad-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529	Pre-made adenovirus	C-3FLAG	coden optimized for mamamlian
GMV-V-2019nCoV-197	pGMLV-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) Omicron variant aka B.1.1.529	Lentiviral vector	C-3FLAG	coden optimized for mamamlian

    《药诺基因protocol-基于新冠假病毒的抗体及疫苗筛选及中和性效价评估》 申请    

邮件至 support@genemedi.cn

申请邮件格式：
主题：《药诺基因protocol-基于新冠假病毒的抗体及疫苗筛选及中和性效价评估》 申请
邮件内容：
申请人姓名：
申请人手机：
邮箱：
单位：



    药诺基因SARS-CoV-2 新冠假病毒细胞进入实验   

 

图注:药诺基因提供的SARS-CoV-2(2019nCoV)假病毒感染HEK293T细胞72小时后，利用荧光(A)、流式细胞
分析(B)和荧光素酶活性(C)实验验证假病毒进入细胞的效率。实验结果表明hACE2显著提高了SARS-CoV-2
PSV的感染效率。药诺基因提供的SARS-CoV-2假病毒为SARS-CoV-2感染、疫苗疗效评估和中和抗体效价检
测等提供了良好的工具。




    联系方式    

张小姐
Email: support@genemedi.cn
Tel: +86-21-50478399